陕西督导中医药传承创新工程项目建设

2018-05-31 孔 群 中国中医

近日,陕西省中医药管理局组织专家对该省入选国家中医药传承创新工程项目库的单位进行实地督导检查。专家组通过听取项目进展汇报、查阅相关资料、现场讨论提问、实地考察等形式,从医院基础设施、重点专科、中医诊疗模式、中医医疗技术、中药药事服务能力、人才培养、临床科研一体化以及信息化建设等方面进行了督导检查。

近日,陕西省中医药管理局组织专家对该省入选国家中医药传承创新工程项目库的单位进行实地督导检查。专家组通过听取项目进展汇报、查阅相关资料、现场讨论提问、实地考察等形式,从医院基础设施、重点专科、中医诊疗模式、中医医疗技术、中药药事服务能力、人才培养、临床科研一体化以及信息化建设等方面进行了督导检查。

专家组要求,各项目单位要进一步提高认识、优化方案、落实责任、夯实资金安全管理,严格依据国家规定的项目建设内容与要求,加快办理项目前期手续,推动项目早日开工建设,并依法合规做好建设工作。在抓好硬件建设的同时重点强化内涵建设能力提升,整合优势资源,压实责任,倒排工期,全力推进项目建设,确保按期完成中医药传承创新工程建设。

陕西省有5家单位入选国家中医药传承创新工程项目库,其中陕西省中医药研究院为中医药科研机构建设项目单位,陕西中医药大学附属医院,西安市、宝鸡市、安康市中医医院等4家医院为重点中医医院建设项目单位。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1819888, encodeId=84f5181988812, content=<a href='/topic/show?id=d7c410008952' target=_blank style='color:#2F92EE;'>#项目建设#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100089, encryptionId=d7c410008952, topicName=项目建设)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue Mar 19 01:24:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796820, encodeId=30681e96820c0, content=<a href='/topic/show?id=969121500e5' target=_blank style='color:#2F92EE;'>#中医药传承创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21500, encryptionId=969121500e5, topicName=中医药传承创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Thu Feb 14 02:24:00 CST 2019, time=2019-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675586, encodeId=46ff16e5586ce, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Wed Sep 19 19:24:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285581, encodeId=cb9c1285581fc, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Jun 02 12:24:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409547, encodeId=2345140954ea3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jun 02 12:24:00 CST 2018, time=2018-06-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1819888, encodeId=84f5181988812, content=<a href='/topic/show?id=d7c410008952' target=_blank style='color:#2F92EE;'>#项目建设#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100089, encryptionId=d7c410008952, topicName=项目建设)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue Mar 19 01:24:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796820, encodeId=30681e96820c0, content=<a href='/topic/show?id=969121500e5' target=_blank style='color:#2F92EE;'>#中医药传承创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21500, encryptionId=969121500e5, topicName=中医药传承创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Thu Feb 14 02:24:00 CST 2019, time=2019-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675586, encodeId=46ff16e5586ce, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Wed Sep 19 19:24:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285581, encodeId=cb9c1285581fc, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Jun 02 12:24:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409547, encodeId=2345140954ea3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jun 02 12:24:00 CST 2018, time=2018-06-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1819888, encodeId=84f5181988812, content=<a href='/topic/show?id=d7c410008952' target=_blank style='color:#2F92EE;'>#项目建设#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100089, encryptionId=d7c410008952, topicName=项目建设)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue Mar 19 01:24:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796820, encodeId=30681e96820c0, content=<a href='/topic/show?id=969121500e5' target=_blank style='color:#2F92EE;'>#中医药传承创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21500, encryptionId=969121500e5, topicName=中医药传承创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Thu Feb 14 02:24:00 CST 2019, time=2019-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675586, encodeId=46ff16e5586ce, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Wed Sep 19 19:24:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285581, encodeId=cb9c1285581fc, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Jun 02 12:24:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409547, encodeId=2345140954ea3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jun 02 12:24:00 CST 2018, time=2018-06-02, status=1, ipAttribution=)]
    2018-09-19 lishizhe
  4. [GetPortalCommentsPageByObjectIdResponse(id=1819888, encodeId=84f5181988812, content=<a href='/topic/show?id=d7c410008952' target=_blank style='color:#2F92EE;'>#项目建设#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100089, encryptionId=d7c410008952, topicName=项目建设)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue Mar 19 01:24:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796820, encodeId=30681e96820c0, content=<a href='/topic/show?id=969121500e5' target=_blank style='color:#2F92EE;'>#中医药传承创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21500, encryptionId=969121500e5, topicName=中医药传承创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Thu Feb 14 02:24:00 CST 2019, time=2019-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675586, encodeId=46ff16e5586ce, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Wed Sep 19 19:24:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285581, encodeId=cb9c1285581fc, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Jun 02 12:24:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409547, encodeId=2345140954ea3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jun 02 12:24:00 CST 2018, time=2018-06-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1819888, encodeId=84f5181988812, content=<a href='/topic/show?id=d7c410008952' target=_blank style='color:#2F92EE;'>#项目建设#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100089, encryptionId=d7c410008952, topicName=项目建设)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Tue Mar 19 01:24:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796820, encodeId=30681e96820c0, content=<a href='/topic/show?id=969121500e5' target=_blank style='color:#2F92EE;'>#中医药传承创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21500, encryptionId=969121500e5, topicName=中医药传承创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Thu Feb 14 02:24:00 CST 2019, time=2019-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675586, encodeId=46ff16e5586ce, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Wed Sep 19 19:24:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285581, encodeId=cb9c1285581fc, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Jun 02 12:24:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409547, encodeId=2345140954ea3, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jun 02 12:24:00 CST 2018, time=2018-06-02, status=1, ipAttribution=)]
    2018-06-02 仁医06

相关资讯

陕西鼓励优先使用低价药品 降低患者药费

4月12日,陕西省卫计委发出《关于进一步做好药品和高值医用耗材网采工作的通知》,鼓励优先使用低价药品。各采购联合体和各级医疗机构在低价药品的议价和采购中,要按照不超过低价药品日均费用标准的原则采购,让低价药品价格合理回归,充分保障低价药品供应。在同类药品中,要优先采购、使用低价药品,最大限度降低患者用药费用。为完善药品采购平台,4月起省药械集中采购平台将整合现有基层、县级和城市医疗机构3个药品数据

陕西大规模调整耗材价格 必须全国很低

陕西动态调价又启动了,共涉及11类高值耗材,涉及企业和品种,无疑也是很多的了。5月4日,陕西省卫计委办公室发布了《关于开展神经外科等11大类医用耗材动态调整的通知》,本次动态调整涉及11大类高值医用耗材,具体包括:眼科、吻合器、电生理、结构心脏病、体外循环及血液净化、疝修补、人工器官组织、神经外科、非血管介入、起博器、口腔科。本次通知,调整的内容包括“限价挂网目录”价格动态调整、“限价挂网目录”品

陕西省计划将贫困户全部纳入新农合和大病保险

记者从5月7日召开的陕西省推进健康扶贫工作暨整改部署电视电话会上了解到,目前我省还有52个贫困县,4961个贫困村,180多万贫困人口。今年,全省计划完成23个贫困县摘帽,3303个贫困村退出,101.7万贫困人口脱贫,脱贫人数是去年的2.5倍,占到全国脱贫任务的十分之一。针对当前在健康扶贫工作中,一些地方还存在盲目拔高标准、政策落实不到位,贫困地区特别是深度贫困地区医疗卫生服务体系薄弱,乡村两级

西北大学和西北工业大学重建医学院到底是为了啥?

为什么在不到一年的时间里,西北大学和西北工业大学都要在医学院方面下功夫,而且增设自己的附属医院呢?

陕西为贫困地区招全科医生

记者近日从陕西省卫生计生委获悉,陕西省今年计划为深度贫困地区乡镇卫生院招录100名具有执业(助理)医师证的全科医生。

陕西为基层医疗机构招聘2415人 很低服务5年

定向招聘医学类本科毕业生纳入事业单位编制内管理;试用期满考核合格,一次性补助安家费3万元。